U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H12N2O3
Molecular Weight 208.2139
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PICAMILON

SMILES

OC(=O)CCCNC(=O)C1=CC=CN=C1

InChI

InChIKey=NAJVRARAUNYNDX-UHFFFAOYSA-N
InChI=1S/C10H12N2O3/c13-9(14)4-2-6-12-10(15)8-3-1-5-11-7-8/h1,3,5,7H,2,4,6H2,(H,12,15)(H,13,14)

HIDE SMILES / InChI

Molecular Formula C10H12N2O3
Molecular Weight 208.2139
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Picamilon (also known as N-nicotinoyl-GABA, Pycamilon, and Pikamilon) is a drug formed by a synthetic combination of niacin and GABA. It was developed in the Soviet Union in 1969 and further studied in both Russia and Japan as a prodrug of GABA. Picamilon permeated the blood-brain barrier and then is hydrolyzed into GABA and niacin. The released GABA, in theory, would activate GABA receptors potentially producing an anxiolytic response. The second released component, niacin, is a vasodilator. Today picamilon is sold in Russia as a prescription drug and is used for the treatment of a variety of illnesses and disorders, ranging from depression to a migraine, neuro infections, senile psychosis, certain types of glaucoma, and even acute alcohol intoxication. As of 2015, the FDA classified picamilon as a substance that does not meet the requirements of a dietary supplement and is therefore no longer permitted to be sold in the United States.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Пикамилон
Primary
Пикамилон
Primary
Пикамилон
Primary
Пикамилон

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
cerebrovascular diseases - 0,02-0,05 g 2-3 times for 1-2 months; depression - on 0,04-0,2 g in 2-3 receptions in day within 1,5-3 months; as an anti-asthenic and tranquilizing agent - 0,04-0,08 g per day, in some cases - up to 0,2-0,3 g per day for 1-1,5 months; alcoholism: 0.1-0.15 g per day (course - 6-7 days)
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Record UNII
0S5N9SEK4N
Record Status Validated (UNII)
Record Version